AC Immune’s Parkinson’s Therapy ACI-7104 Gains FDA Fast Track Status — AC Immune SA

Event summary

AC Immune’s ACI-7104, an anti-alpha-synuclein active immunotherapy for early Parkinson’s disease, received FDA Fast Track designation on August 11, 2026.
The company also secured IND clearance to expand its Phase 2 VacSYn trial to U.S. sites.
Interim results showed safety, tolerability, and a 100% immunogenicity responder rate with early signals of activity.
Full week-100 results from Part 1 of the VacSYn trial are expected in H2 2026.

The big picture

AC Immune’s Fast Track designation for ACI-7104 underscores the growing focus on active immunotherapies targeting alpha-synuclein, a key protein linked to Parkinson’s disease. The strategic shift toward wholly-owned programs reflects a broader industry trend of biopharmaceutical companies prioritizing proprietary pipelines to address unmet needs in neurodegenerative diseases. With over $4.5 billion in potential milestone payments from existing partnerships, AC Immune is positioning itself as a leader in this space.

What we're watching

Clinical Efficacy: Whether the full week-100 results from Part 1 of the VacSYn trial will confirm early signals of activity and support further development.
Regulatory Momentum: The pace at which AC Immune can leverage FDA Fast Track designation to accelerate ACI-7104’s path to market.
Funding and Partnerships: How the $4 million grant from the Vijay and Marie Goradia Charitable Foundation will impact long-term safety and efficacy assessments.